Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
7
×
life sciences
national blog main
boston top stories
clinical trials
ipo
san francisco blog main
cancer drugs
fda
national top stories
new york blog main
san francisco top stories
sanofi
europe blog main
new york top stories
venture capital
biogen
boulder/denver blog main
boulder/denver top stories
deals
deerfield management
detroit blog main
detroit top stories
drug discovery
europe top stories
gilead sciences
indiana blog main
indiana top stories
investing
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
san diego blog main
san diego top stories
san francisco
What
ipo
7
×
medicines
7
×
cancer
new
research
bio
covid
drug
proteins
revolution
roundup
targets
acquisitions
activity
announced
approvals
based
begin
biogen
biosciences
biotech
bio’s
black
brings
bubbles
cancer’s
cells
ceo
clamped
class
clinic
clinical
codiak
collabs
companies
company’s
course
daniel
deal
delays
Language
unset
Current search:
medicines
×
cancer
×
ipo
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic